0000000000064403

AUTHOR

K. Höffken

showing 3 related works from this author

Requestioning depression in patients with cancer: Contribution of somatic and affective symptoms to Beck's Depression Inventory

2007

Background: Depressive symptoms are a major complaint reported by cancer patients. Somatic and affective symptoms can contribute to depression. Patients and methods: We investigated the prevalence of somatic and affective depressive symptoms with the Beck Depression Inventory (BDI) in 213 hospitalized cancer patients prior to the start of chemotherapy. Results: Seventeen of 213 patients (8%) were screened positive for major depression; 40 (19%) had mild to moderate depressive symptoms. The corresponding figures for somatic and affective symptoms were 33.3% and 2.8% in the patients with major depression and 23.0% and 8.0% in those with mild to moderate depressive symptoms. Female patients, p…

AdultMalemedicine.medical_specialtyAdolescentComorbidityRisk AssessmentStatistics NonparametricHospitals UniversityAge DistributionQuality of lifeGermanyNeoplasmsSickness Impact ProfileSurveys and QuestionnairesInternal medicineAdaptation PsychologicalInterview PsychologicalPrevalencemedicineHumansSex DistributionPsychiatryDepression (differential diagnoses)AgedProbabilityPsychiatric Status Rating ScalesDepressive Disorderbusiness.industryCase-control studyBeck Depression InventoryCancerHematologyMiddle Agedmedicine.diseaseComorbidityChemotherapy regimenCausalityOncologyCase-Control StudiesQuality of LifeMajor depressive disorderFemalebusinessStress PsychologicalFollow-Up StudiesAnnals of Oncology
researchProduct

Depression and functional impairment independently contribute to decreased quality of life in cancer patients prior to chemotherapy

2007

An inverse association either between depression or impaired functional status and quality of life (QoL) has been reported for cancer patients, but the independent effect of depression or depressive symptoms and of functional impairment on QoL is unclear.We investigated the prevalence of depression or depressive symptoms with the Beck Depression Inventory (BDI), the functional impairment with the ECOG-Performance-Status (ECOG-PS) and the QoL with the EORTC-QLQ-C30 questionnaire in a sample of 175 hospitalised cancer patients prior to the start of chemotherapy.Sixteen of 175 patients (9.1%) screened positive for major depression, 29 (16.6%) had mild to moderate depressive symptoms. In 11 of …

AdultMalemedicine.medical_specialtyTime FactorsAdolescentPsychometricsPsychometricsHealth StatusQuality of lifeNeoplasmsSurveys and QuestionnairesInternal medicinePrevalencemedicineHealth Status IndicatorsHumansRadiology Nuclear Medicine and imagingPsychological testingProspective StudiesKarnofsky Performance StatusProspective cohort studyLife StyleneoplasmsFatigueDepression (differential diagnoses)AgedAged 80 and overAnalysis of VarianceDepressive Disorder MajorPsychological TestsUnivariate analysisDepressionbusiness.industryBeck Depression InventoryCancerHematologyGeneral MedicineMiddle Agedmedicine.diseaseHealth SurveyshumanitiesOncologyQuality of LifePhysical therapyFemalebusinessActa Oncologica
researchProduct

Low-Dose Aclacinomycin and Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute Myelogenous Leukemia

1990

Nineteen patients with relapsed or refractory acute myelogenous leukemia were treated with escalating doses of aclacinomycin (ACLA 20–30 mg/m2 daily for 5 days) and intermediate-dose cytosine arabinoside (Ara-C 1 g/m2 twice daily for 4 days). Most patients had received previous therapy with high- or intermediate-dose Ara-C plus mitoxantrone (HAM, IAM) and TAD (6-thioguanine, standard-dose cytosine arabinoside, and daunorubicin). Four patients had had repeated relapses and another three were treated for primary treatment failure following induction with HAM or I AM.

medicine.medical_specialtyMitoxantroneDaunorubicinbusiness.industryLow dosemedicine.diseaseGastroenterologyMyelogenouschemistry.chemical_compoundLeukemiaRefractorychemistryInternal medicinemedicinePrimary treatmentbusinessCytosinemedicine.drug
researchProduct